

ARTIFICIAL INTELLIGENCE-ENABLED TUMOR MICROENVIRONMENT MODELING: INTEGRATING SPATIAL BIOLOGY, MULTI-OMICS, AND DIGITAL TWINS

^{#1} **Dr. Aditya Menon**, Professor, Department of Oncology,
Sri Siddhartha Medical College, Tumakuru, India
Adityamenon77@gmail.com

Abstract: The tumor microenvironment (TME) has emerged as one of the most important determinants of cancer initiation, progression, metastasis, immune evasion, and therapeutic response. Rather than functioning as an isolated population of malignant cells, tumors exist within highly dynamic ecosystems comprising immune cells, stromal fibroblasts, endothelial cells, extracellular matrix components, vascular networks, signaling molecules, metabolites, and microbiota that collectively shape disease evolution. Conventional analytical approaches frequently investigate these biological components independently, limiting comprehensive understanding of tumor ecosystem dynamics. Recent advances in artificial intelligence (AI), particularly foundation models, multimodal transformers, graph neural networks, self-supervised learning, spatial computing, and generative AI, have enabled comprehensive computational modeling of the TME through integration of spatial biology, multi-omics, digital pathology, radiological imaging, laboratory biomarkers, liquid biopsy, electronic health records, and longitudinal clinical data. These intelligent systems support biomarker discovery, molecular characterization, prognostic prediction, immunotherapy optimization, adaptive treatment planning, digital twin simulation, and intelligent clinical decision support while advancing systems oncology and precision medicine. Emerging innovations including multimodal large language models, federated learning, reinforcement learning, retrieval-augmented generation, explainable artificial intelligence, and agentic AI further strengthen computational modeling of tumor ecosystems by enabling collaborative, privacy-preserving, and continuously adaptive biomedical intelligence. Despite remarkable technological progress, important scientific, technical, ethical, and regulatory challenges remain regarding multimodal data harmonization, computational scalability, interoperability, interpretability, cybersecurity, clinical validation, and equitable implementation. This review provides a comprehensive overview of AI-enabled tumor microenvironment modeling, emphasizing integration of spatial biology, multi-omics, and digital twins as a transformative paradigm for personalized oncology.[1]

Keywords: Tumor microenvironment, Artificial intelligence, Spatial biology, Digital twins, Multi-omics, Foundation models, Precision oncology, Computational oncology, Systems oncology, Clinical decision support.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and the source are properly cited.

1. Introduction

Cancer is increasingly recognized as a dynamic ecosystem in which malignant cells continuously interact with immune populations, stromal fibroblasts, endothelial cells, extracellular matrix components, vascular networks, cytokines, chemokines, metabolites, and host physiological systems. These interactions collectively influence tumor initiation, progression, metastatic

dissemination, immune escape, therapeutic resistance, and long-term clinical outcomes.[2]

Traditional oncology has largely focused on intrinsic characteristics of malignant cells, including genomic alterations and histopathological morphology. Although these approaches remain fundamental to cancer diagnosis, they often fail to capture the highly dynamic biological interactions occurring within

the tumor microenvironment (TME) that determine therapeutic responsiveness and disease evolution.[3]

Recent advances in spatial biology, multi-omics technologies, digital pathology, radiological imaging, liquid biopsy, and systems biology have generated unprecedented opportunities for comprehensive characterization of tumor ecosystems. Artificial intelligence now enables integration of these heterogeneous biomedical modalities into unified computational frameworks capable of modeling complex biological interactions across molecular, cellular, tissue, and clinical scales.[4]

The convergence of AI, spatial biology, digital twins, and precision medicine therefore represents a transformative paradigm for understanding tumor biology and enabling adaptive personalized oncology throughout the cancer care continuum.[5]

2. Evolution of Tumor Microenvironment Modeling

Early cancer research primarily emphasized malignant cell biology while treating surrounding stromal tissues as passive structural elements. Subsequent discoveries demonstrated that immune cells, fibroblasts, endothelial cells, extracellular matrix proteins, vascular networks, inflammatory mediators, and metabolic interactions actively regulate tumor development, metastatic dissemination, and therapeutic response.[6]

Advances in single-cell sequencing, spatial transcriptomics, multiplex immunohistochemistry, imaging mass cytometry, and computational pathology substantially expanded understanding of cellular organization within tumor ecosystems. Simultaneously, radiomics, genomics, proteomics, metabolomics, and systems biology generated complementary information describing tumor biology across multiple organizational scales.

Artificial intelligence subsequently enabled computational integration of these diverse biomedical datasets, while foundation AI models introduced generalized multimodal representation learning capable of modeling complex tumor ecosystems rather than isolated biological variables.

Today, AI-enabled tumor microenvironment modeling integrates systems biology, computational oncology, digital health, and multimodal artificial intelligence into unified computational ecosystems supporting precision oncology.[7]

3. Principles of AI-Enabled Tumor Microenvironment Modeling

Artificial intelligence-enabled tumor microenvironment modeling is founded upon the principle that cancer behavior emerges from dynamic interactions among multiple interconnected biological systems rather than isolated molecular abnormalities. Foundation AI models integrate heterogeneous biomedical information into unified patient-specific computational representations capable of continuously modeling evolving tumor ecosystems.[8]

Self-supervised learning enables discovery of latent biological relationships without extensive manual annotation, while multimodal transformer architectures align radiological imaging, digital pathology, spatial biology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, and longitudinal clinical trajectories within shared computational embedding spaces.

Graph neural networks further model relationships among malignant cells, immune populations, stromal fibroblasts, endothelial cells, extracellular matrix components, signaling pathways, metabolites, therapeutic targets, and clinical outcomes, thereby enabling systems-level computational reasoning regarding tumor evolution and therapeutic response.[9]

4. Computational Architecture

Modern tumor microenvironment modeling platforms consist of interconnected computational layers responsible for multimodal biomedical data acquisition, preprocessing, representation learning, ecosystem simulation, adaptive learning, predictive analytics, digital twin modeling, and intelligent clinical decision support.[10]

The acquisition layer continuously incorporates radiological imaging, digital pathology, genomic

sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, liquid biopsy, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, and synchronize temporal patient information.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological function, and longitudinal clinical trajectories. Ecosystem simulation modules continuously update these computational representations while supporting prediction of disease progression, therapeutic response, immune adaptation, recurrence, and survival.[11]

5. Spatial Biology and Artificial Intelligence

Spatial biology has revolutionized understanding of tumor ecosystems by preserving the spatial organization of cells while simultaneously measuring gene expression, protein abundance, immune-cell localization, metabolic activity, and cellular communication. Unlike conventional bulk sequencing, spatial technologies reveal how neighboring cells influence one another within complex tissue environments.[12]

Artificial intelligence integrates spatial transcriptomics, multiplex immunohistochemistry, imaging mass cytometry, digital pathology, and radiological imaging into unified computational representations capable of identifying immune niches, invasion fronts, stromal remodeling, angiogenic regions, hypoxic zones, and metastatic microenvironments.

Foundation AI models automatically learn hierarchical spatial representations while graph neural networks characterize communication among neighboring cellular populations, substantially improving biological understanding of tumor ecosystem organization and therapeutic responsiveness.[13]

6. Multi-Omics Integration

Comprehensive characterization of the tumor microenvironment increasingly depends upon integration of genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, lipidomics, and single-cell sequencing into unified molecular representations of evolving tumor biology.[14]

Foundation AI models utilize multimodal transformers, graph neural networks, biological knowledge graphs, and self-supervised learning to identify complex relationships among genes, proteins, metabolites, signaling pathways, immune responses, spatial organization, imaging phenotypes, and therapeutic targets that remain difficult to detect using isolated analytical approaches.

These integrated molecular representations substantially improve biomarker discovery, molecular subtype classification, therapeutic response prediction, systems biology research, and personalized precision medicine while strengthening computational modeling of tumor ecosystems.[15]

7. Artificial Intelligence for Cellular Ecosystem Modeling

The tumor microenvironment consists of highly heterogeneous cellular populations exhibiting distinct biological functions and continuously evolving interactions. Malignant cells coexist with cytotoxic T lymphocytes, regulatory T cells, macrophages, dendritic cells, natural killer cells, cancer-associated fibroblasts, endothelial cells, adipocytes, and additional stromal components that collectively determine disease progression and therapeutic responsiveness.[16]

Artificial intelligence integrates single-cell RNA sequencing, spatial transcriptomics, multiplex immunohistochemistry, flow cytometry, and computational pathology into comprehensive computational representations of cellular ecosystems. Machine learning identifies biologically significant cellular subpopulations associated with immune escape, angiogenesis, metastatic dissemination, therapeutic resistance, recurrence, and disease progression.

Graph neural networks characterize communication among neighboring cellular

populations, thereby enabling systems-level understanding of tumor-immune interactions and supporting individualized therapeutic strategies.[17]

8. Digital Pathology and Microenvironment Intelligence

Digital pathology provides microscopic characterization of tissue architecture, immune infiltration, stromal remodeling, extracellular matrix organization, angiogenesis, fibrosis, necrosis, and cellular morphology. Whole-slide imaging combined with foundation AI models enables comprehensive computational analysis of millions of cells simultaneously while preserving spatial tissue organization.[18]

Transformer architectures learn generalized histomorphological representations transferable across multiple cancer types, whereas graph neural networks characterize interactions among malignant cells, immune populations, stromal fibroblasts, vascular structures, and extracellular matrix components. Integration of computational pathology with spatial biology and multi-omics substantially improves tumor microenvironment characterization, biomarker discovery, immunotherapy prediction, and precision oncology while enabling comprehensive computational ecosystem intelligence.[19]

9. Digital Twins for Tumor Ecosystem Simulation

Digital twin technology extends tumor microenvironment modeling by creating continuously evolving virtual representations of individual patients synchronized with serial imaging examinations, computational pathology, spatial biology, multi-omics, laboratory biomarkers, wearable physiological monitoring, and longitudinal clinical information. These adaptive virtual ecosystems simulate tumor evolution, immune remodeling, stromal adaptation, angiogenesis, therapeutic response, treatment-related toxicity, recurrence, and metastatic dissemination while enabling proactive precision oncology through individualized computational simulation.[20]

10. Artificial Intelligence for Predicting Therapeutic Response

One of the most clinically significant applications of AI-enabled tumor microenvironment modeling is the prediction of therapeutic response through comprehensive characterization of dynamic ecosystem interactions. Foundation AI models integrate radiological imaging, digital pathology, spatial biology, multi-omics, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, and longitudinal clinical outcomes into unified computational representations capable of forecasting treatment efficacy across multiple therapeutic modalities.[21]

Unlike conventional predictive models based on isolated molecular biomarkers, ecosystem-based artificial intelligence simultaneously evaluates immune-cell infiltration, stromal remodeling, extracellular matrix organization, angiogenesis, metabolic adaptation, clonal evolution, cytokine signaling, and spatial cellular communication that collectively determine therapeutic responsiveness. These intelligent systems estimate responses to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, adoptive cellular therapies, and multimodal treatment combinations while continuously updating predictions as tumor biology evolves.

Such predictive ecosystem modeling enables clinicians to personalize therapeutic strategies while minimizing treatment-related toxicity and improving long-term clinical outcomes.

11. Precision Immuno-Oncology and Immune Ecosystem Intelligence

Immunotherapy has highlighted the importance of accurately modeling the tumor immune ecosystem because therapeutic success depends upon dynamic interactions among malignant cells, cytotoxic lymphocytes, macrophages, dendritic cells, regulatory T cells, endothelial cells, fibroblasts, extracellular matrix components, and inflammatory mediators. Foundation AI models integrate computational pathology, spatial transcriptomics, immunomics, radiomics, laboratory biomarkers, and longitudinal clinical outcomes into comprehensive computational

representations of immune ecosystem dynamics.[22]

Graph neural networks model communication among immune populations while transformer architectures identify latent relationships among molecular pathways, tissue architecture, imaging phenotypes, and therapeutic response. Digital twins further simulate immune activation, immune escape, cytokine signaling, stromal remodeling, angiogenesis, and mechanisms of resistance under alternative therapeutic scenarios.

These intelligent computational ecosystems substantially improve individualized selection of immune checkpoint inhibitors, adoptive cellular therapies, cancer vaccines, bispecific antibodies, and combination immunotherapeutic strategies.

12. Intelligent Clinical Decision Support

AI-enabled tumor microenvironment modeling provides the computational foundation for intelligent clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations. Radiological imaging, digital pathology, molecular diagnostics, spatial biology, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines are synthesized into unified computational environments supporting multidisciplinary oncology care.[23]

Interactive clinical dashboards generate individualized ecosystem analyses, molecular interpretations, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, and survival forecasts while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, molecular biologists, pharmacists, immunologists, and computational scientists.

These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce fragmentation of biomedical information, and promote evidence-based personalized cancer management throughout the cancer care continuum.

13. Continuous Learning and Federated Ecosystem Intelligence

The effectiveness of tumor microenvironment models depends upon their ability to evolve continuously as new biomedical information becomes available. Artificial intelligence integrates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining ecosystem simulations and predictive accuracy.[24]

Federated learning further strengthens these computational ecosystems by enabling collaborative development of foundation AI models across geographically distributed healthcare institutions without requiring centralized sharing of sensitive patient information. Participating organizations securely exchange encrypted model parameters while maintaining local control of biomedical datasets, thereby improving algorithm robustness, fairness, external validity, and global applicability.

The combination of continual learning and federated intelligence establishes adaptive tumor ecosystem models capable of supporting worldwide precision oncology while preserving patient privacy and institutional governance.

14. Explainability, Validation, and Ethical Governance

Successful implementation of AI-enabled tumor microenvironment modeling requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual explanations identifying the imaging, molecular, spatial, pathological, physiological, and clinical variables responsible for predictive outputs.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon protection of patient privacy, informed consent, transparency, accountability, equitable access, responsible data stewardship, and continuous post-deployment surveillance to ensure trustworthy integration of tumor ecosystem intelligence into routine oncology practice.

15. Future Perspectives

Future tumor microenvironment intelligence platforms will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, liquid biopsy, quantum computing, Internet of Medical Things (IoMT) technologies, robotics, cloud-native healthcare infrastructure, and autonomous clinical reasoning systems into unified computational oncology ecosystems.[26]

These next-generation platforms will continuously integrate molecular biology, imaging, pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, and real-world clinical outcomes while autonomously coordinating diagnostic workflows, optimizing therapeutic strategies, supporting adaptive clinical trials, generating personalized patient communication, and continuously synthesizing biomedical evidence.

Such intelligent tumor ecosystem platforms are expected to transform oncology from fragmented and reactive disease management toward predictive, preventive, adaptive, continuously learning, and precision-guided healthcare across the global cancer community.

16. Discussion

Artificial intelligence-enabled tumor microenvironment modeling represents one of the most significant paradigm shifts in computational

oncology by integrating spatial biology, multi-omics, digital twins, and systems biology into unified computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional approaches that evaluate isolated biological components, these intelligent systems simultaneously analyze molecular biology, cellular interactions, tissue architecture, imaging phenotypes, laboratory biomarkers, physiological monitoring, and longitudinal clinical trajectories to generate holistic representations of evolving tumor ecosystems.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, continuous learning, federated collaboration, systems oncology, and intelligent clinical decision support demonstrate the extraordinary potential of ecosystem-based artificial intelligence to redefine future cancer care. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, AI-enabled tumor ecosystem modeling is expected to become a foundational computational infrastructure supporting next-generation precision oncology.

17. Conclusion

Artificial intelligence-enabled tumor microenvironment modeling is redefining precision oncology by integrating spatial biology, multi-omics, digital pathology, radiological imaging, laboratory biomarkers, wearable technologies, electronic health records, digital twins, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting predictive, preventive, adaptive, and continuously personalized cancer care throughout the disease continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning,

reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen these intelligent ecosystems, enabling increasingly accurate characterization of tumor evolution, biomarker discovery, therapeutic optimization, adaptive disease monitoring, evidence-based clinical decision-making, and continuously personalized oncology care.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, immunologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of AI-enabled tumor microenvironment modeling. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, accelerate translational research, and establish a new era of intelligent, adaptive, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) 'Enhancing Precision Oncology Through Multimodal Data Integration', *Nature Reviews Clinical Oncology*, 20(4), pp. 267-283.
2. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', *Nature Cancer*, 3(7), pp. 789-799.
3. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', *Clinical Cancer Research*, 27(5), pp. 1248-1259.
4. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', *Nature Genetics*, 45(10), pp. 1113-1120.
5. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', *IEEE Transactions on Medical Imaging*, 40(8), pp. 2021-2037.
6. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', *Nature*, 616(7956), pp. 259-265.
7. Hanahan D. Hallmarks of cancer: new dimensions. *Cancer Discov.* 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
8. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. *Nature.* 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
9. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. *Nature.* 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
10. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. *Nature.* 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
11. 11. 30. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. *arXiv.* 2021. Doi:10.48550/arXiv.2108.07258.
12. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. *arXiv.* 2020. Doi:10.48550/arXiv.2010.11929.
13. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/321>, DOI: <https://doi.org/10.46121/pspc.51.4.4>
14. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/304>, DOI: <https://doi.org/10.46121/pspc.51.2.7>
15. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', *Cancer Cell*, 40(8), pp. 805-823.
16. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA

SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/323>, DOI: <https://doi.org/10.46121/pspc.51.4.5>

17. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/303>, DOI: <https://doi.org/10.46121/pspc.52.1.5>

18. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/324>, DOI: <https://doi.org/10.46121/pspc.52.2.14>

19. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/311>, DOI: <https://doi.org/10.46121/pspc.52.2.12>

20. Dr. RajathaMaradiHemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/345>, DOI: <https://doi.org/10.46121/pspc.52.2.18>

21. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN:

1674-3415, <https://pspac.info/index.php/dlbh/article/view/388>, DOI: <https://doi.org/10.46121/pspc.51.4.7>

22. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/325>, DOI: <https://doi.org/10.46121/pspc.52.4.14>

23. Dr. RajathaMaradiHemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, <https://pspac.info/index.php/dlbh/article/view/343>, DOI: <https://doi.org/10.46121/pspc.52.4.16>

24. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

25. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: <https://pspac.info/index.php/dlbh/article/view/312>, DOI: <https://doi.org/10.46121/pspc.52.4.13>.

26. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.

27. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN: 1674-3415, <https://pspac.info/index.php/dlbh/article/view/389>, DOI: <https://doi.org/10.46121/pspc.51.4.8>

28. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical



- Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
29. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
30. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.